Evidence map›Paper›PMID 40219580›Full record

ArticleJournal of labelled compounds & radiopharmaceuticals2025

Radiosynthesis and Evaluation of [

Romy Cools, Koen Vermeulen, Sofie Celen, Renan C F Leitao, Guy Bormans

Abstract read
In one paragraph

Article in Journal of labelled compounds & radiopharmaceuticals, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. FirstResearch square · 2026
    Article
  2. Review
  3. [EJNMMI radiopharmacy and chemistry · 2025
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Romy CoolsLaboratory for Radiopharmaceutical Research, Department of Pharmacy and Pharmacological Sciences, KU Leuven, Leuven, Belgium.ORCID https://orcid.org/0000-0002-6883-4031
Koen VermeulenNuclear Medical Applications Institute, Belgian Nuclear Research Centre (SCK CEN), Mol, Belgium.
Sofie CelenNuclear Medicine and Molecular Imaging, UZ Leuven, Leuven, Belgium.
Renan C F LeitaoLaboratory for Radiopharmaceutical Research, Department of Pharmacy and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Guy BormansLaboratory for Radiopharmaceutical Research, Department of Pharmacy and Pharmacological Sciences, KU Leuven, Leuven, Belgium.

Funding

Fonds Wetenschappelijk Onderzoek G0A6222NKU Leuven C24E/19/070
6 · The paper itself

Abstract

Heat shock protein 90 (Hsp90) is a critical chaperone in the protein quality control system, essential for maintaining cellular proteostasis. Aberrant Hsp90 function has been implicated in cancer and neurodegenerative disorders, making it an attractive therapeutic target and a potential biomarker for disease characterisation and progression using PET imaging. In this study, we aimed to develop the first fluorine-18 labelled brain permeable PET imaging agent, [

Indexed as

Fluorine RadioisotopesHSP90 Heat-Shock ProteinsPositron-Emission TomographyRadiopharmaceuticalsAnimalsBrainBrain NeoplasmsCell Line, TumorGlioblastomaHumansIsoxazolesMiceRadiochemistryResorcinolsTissue Distribution5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamideFluorine RadioisotopesHSP90 Heat-Shock ProteinsIsoxazolesRadiopharmaceuticalsResorcinolsbrainHsp90imagingneurodegenerationPETpreclinicaltumour

Identifiers

PMID40219580
PMCPMC11992409

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.